Cancer biomarkers (Q26864429)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cancer biomarkers	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

27 September 2017

Cancer biomarkers (English)

1 reference

Europe PubMed Central

27 September 2017

0 references

author name string

N Lynn Henry

1

1 reference

Europe PubMed Central

27 September 2017

Daniel F Hayes

2

1 reference

Europe PubMed Central

27 September 2017

language of work or name

1 reference

publication date

6 February 2012

1 reference

Europe PubMed Central

27 September 2017

Molecular Oncology

1 reference

Europe PubMed Central

27 September 2017

6

1 reference

Europe PubMed Central

27 September 2017

140-146

1 reference

Europe PubMed Central

27 September 2017

2

1 reference

Europe PubMed Central

27 September 2017

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Biospecimen reporting for improved study quality (BRISQ)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Randomized clinical trials with biomarkers: design issues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Sources of bias in specimens for research about molecular markers for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

The minimum information about a proteomics experiment (MIAPE)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Differential exoprotease activities confer tumor-specific serum peptidome patterns

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

REporting recommendations for tumour MARKer prognostic studies (REMARK)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Clinical trial designs for predictive marker validation in cancer treatment trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Gene expression profiling of breast cancer: a new tumor marker

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Use of proteomic patterns in serum to identify ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Linkage of early-onset familial breast cancer to chromosome 17q21

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5528374

28 September 2017

Commentary: hormone receptor testing in breast cancer: a distress signal from Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLONC.2012.01.010

21 January 2018

American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLONC.2012.01.010

21 January 2018

Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLONC.2012.01.010

21 January 2018

American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLONC.2012.01.010

21 January 2018

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLONC.2012.01.010

21 January 2018

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping

1 reference

https://pubmed.ncbi.nlm.nih.gov/22356776

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration

1 reference

https://pubmed.ncbi.nlm.nih.gov/22356776

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Invasive Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22356776

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.MOLONC.2012.01.010

1 reference

Europe PubMed Central

27 September 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Europe PubMed Central

27 September 2017

1 reference

Europe PubMed Central

27 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26864429&oldid=1963382767"